[ad_1]
© Reuters. FILE PHOTO: A scientist researcher, wearing protective gear, shows a box controlling the air quality in the lab at the Thermo Fisher plant, former Novasep, producing COVID-19 vaccines for AstraZeneca in Seneffe, Belgium, February 10, 2021. REUTERS/Yves H
(Reuters) – Thermo Fisher Scientific Inc (NYSE:) said on Monday it would buy specialty diagnostics firm The Binding Site Group from a shareholder group led by European private equity firm Nordic Capital in an all-cash transaction valued at $2.6 billion.
[ad_2]
Source link
